DOCSLIB.ORG

Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

University of Cincinnati Date: 12/20/2010 I, Arturo R Maldonado , hereby submit this original work as part of the requirements for the degree of Doctor of Philosophy in Developmental Biology. It is entitled: Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors Student's name: Arturo R Maldonado This work and its defense approved by: Committee chair: Jeffrey Whitsett Committee member: Timothy Crombleholme, MD Committee member: Dan Wiginton, PhD Committee member: Rhonda Cardin, PhD Committee member: Tim Cripe 1297 Last Printed:1/11/2011 Document Of Defense Form Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors A dissertation submitted to the Graduate School of the University of Cincinnati College of Medicine in partial fulfillment of the requirements for the degree of DOCTORATE OF PHILOSOPHY (PH.D.) in the Division of Molecular & Developmental Biology 2010 By Arturo Rafael Maldonado B.A., University of Miami, Coral Gables, Florida June 1993 M.D., New Jersey Medical School, Newark, New Jersey June 1999 Committee Chair: Jeffrey A. Whitsett, M.D. Advisor: Timothy M. Crombleholme, M.D. Timothy P. Cripe, M.D. Ph.D. Dan Wiginton, Ph.D. Rhonda D. Cardin, Ph.D. ABSTRACT Since 1999, cancer has surpassed heart disease as the number one cause of death in the US for people under the age of 85. Malignant Peripheral Nerve Sheath Tumor (MPNST), a common malignancy in patients with Neurofibromatosis, and colorectal cancer are midkine- producing tumors with high mortality rates. In vitro and preclinical xenograft models of MPNST were utilized in this dissertation to study the role of midkine (MDK), a tumor-specific gene over- expressed in these tumors and to test the efficacy of a MDK-transcriptionally targeted oncolytic HSV-1 (oHSV). The overall goals of this dissertation were to 1) discover mechanistic insights into the role of MDK in cancer using a feature-enabled bioinformatics approach and to 2) exploit MDK biology to increase the efficacy of oncolytic HSV-1 towards MPNST tumors without compromising safety. To search for mechanistic insights into the role of MDK in cancer, A Pearson correlation of genes that co-express with MDK in 121 microarrays of MPNST and colorectal cancers was performed. A cluster of 348 genes that were co-regulated with MDK were identified. MDK co- expressed genes significantly enriched in functional categories such as DNA replication and cell cycle regulation. Out of 348 genes, 66 are transcription complex genes, many of which have been associated with cancer or shown to be cancer causal genes, such as HMGB1, CREB1, and YY1. To assess upstream regulation of MDK co-expressed genes, a cis-element promoter analysis was performed and predicted enrichment of 4 elements: HLF, NFIL3, MEF2A, and FOXD3, a possible cis-regulatory module. Validation and functional studies are needed to confirm these hypotheses. oHSV has been engineered to be safe by deletion of viral genes necessary for virus replication and killing in normal cells. To target midkine-producing tumors, oHSV-MDK-34.5 iii was engineered for this dissertation which contains the HSV-1 neurovirulence γ134.5 transgene driven by the MDK promoter. The HSV neurovirulence protein ICP34.5 has been shown to increase virus replication and infectivity by preventing the shutdown of host cell protein translation. oHSV-MDK-34.5 targeted MDK-producing MPNST with increased replication and oncolysis yet retains attenuation in normal non-MDK producing tissues. MDK promoter activity and transgene biological activity was confirmed in human MPNST (S462, STS26T) and Ewing sarcoma cells (A673). In vitro replication and cytotoxicity in human fibroblasts and STS26T cells by plaque and MTT assays showed that oHSV-MDK-34.5 increased replication and cytotoxicity compared to the Luciferase-containing control virus, oHSV-MDK-Luc. In contrast, no significant difference in cytotoxicity was detected between these viruses in normal human fibroblasts. oHSV-MDK-34.5 impaired in vivo STS26T tumor growth and increased median survival of tumor-bearing nude mice. No evidence of extratumoral spread of oHSV-MDK-34.5 was found in nude mouse organs 14 days after tumor injection. The novel MDK-targeted oncolytic virus engineered in this dissertation, oHSV-MDK-34.5, successfully impaired human MPNST tumor growth and prolonged the survival of MPNST tumor-bearing mice without compromising tumor-specificity and safety. This oHSV is a new addition to the armamentarium of oncolytic viruses being studied for personalized anti-cancer therapy. iv ©2011 Arturo Rafael Maldonado ALL RIGHTS RESERVED v RESEARCH GRANTS & AWARDS The work in this dissertation was supported by a research award from the National Cancer Institute, grants from the NIH, and a grant from the Shriners Hospitals for Children. NIH NCI National Research Service Award F31 CA132613-01 (Arturo Maldonado PI) R01 DK074055 (Timothy Crombleholme PI) R01 DK072446 (Timothy Crombleholme PI) R01 CA114004 (Timothy Cripe PI) R21 CA133663 (Timothy Cripe PI) Shriners Hospitals for Children Grant 8901 (Timothy Crombleholme PI) vi ACKNOWLEDGEMENTS Most special thanks to my thesis committee members and mentors Drs. Timothy Crombleholme, Timothy Cripe, Jeffrey Whitsett, Dan Wiginton, Rhonda Cardin, Bruce Aronow, Anil Jegga and Punam Malik for your insight, instruction and leadership. Thanks to the students of the University of Cincinnati Graduate Programs in Molecular and Developmental Biology, Cell and Cancer Biology, and Neuroscience: especially Hongyan Zhu, Karunyakanth (KK) Mandapaka, David Hahn, Diva Jonatan and Tom Lu for friendship, scientific discussion and support. Thanks to the members of the Crombleholme, Cripe and Malik laboratories. Special thanks to the Crombleholme laboratory: Chuck Klanke, Jose Fernando Solis Vuletin, Shuichi Katayama, Sundeep Keswani, Foong Lim, Mounira Habli, Louis Le and Stephanie Lang. Also thanks to the Cripe laboratory: Mark Currier, Pin-Yi Wang, William Baird and Jennifer Leddon. Also special thanks to the Malik laboratory: Drs. Tomoyasu Higashimoto and Ping Xia. Very special thanks to Drs. Helen Jones and Yoni Mahller, for the excellent scientific discussions, encouragement, guidance, and friendship. My warmest and deepest gratitude goes to Drs. Timothy Crombleholme and Timothy Cripe for their unbridled support, enthusiasm and mentorship. Without their assistance, this work would not have been possible. Thanks to Paul Steele, M.D., director of the Cincinnati Children’s clinical laboratory for advice and technical assistance. Very special thanks to Jessica and Betsy Honig for scientific discussions and manuscript assistance. Also, thanks to my collaborators Drs. Yoshinaga Saeki, E. Antonio Chiocca, Balveen Kaur (The Ohio State University), Robert Cohen (University of Cincinnati), Ian Mohr (SUNY at Stony Brook). Thanks to Michael Burhans, John Shannon vii (Cincinnati Children’s Research Foundation), and Kazunari Yokoyama (RIKEN Institute, Ibaraki, Japan) for kindly providing advice and reagents. My warmest and special thanks to Katrina and my family for unwavering love and support. viii TABLE OF CONTENTS ABSTRACT .................................................................................................................................. iii RESEARCH GRANTS & AWARDS ........................................................................................ vi ACKNOWLEDGEMENTS ....................................................................................................... vii LIST OF FIGURES AND TABLES .......................................................................................... xii CHAPTER 1: General Introduction ........................................................................................... 1 Overall background and clinical significance .......................................................................................... 1 A brief history of chemotherapy and the advent of molecular therapy for cancer ................................... 2 Oncolytic Viruses: Cancer killing viruses as an emerging treatment for cancer ...................................... 4 The era of recombinant viral oncolytics: increasing oncolytic efficacy and biosafety ............................. 6 Virus-mediated cancer cell lysis ............................................................................................................... 7 Transcriptional targeting: an approach to increasing oncolytic efficacy and to personalized predictive oncologic medicine ................................................................................................................................... 7 Advantages of Oncolytic HSV (oHSV) for cancer treatment .................................................................. 8 The research problem: improving oncolytic HSV-1 efficacy without compromising biosafety .............. 9 The oHSV constructed for transcriptional targeting: oHSV-MDK-34.5 .................................................. 9 The role of the HSV-1 protein ICP34.5 in evading viral host defense ................................................... 10 Developmental and cancer-specific MDK expression ........................................................................... 11 Transcriptional regulation and systems biological analyses of the MDK promoter in cancer ............... 12 Transcriptional targeting using the MDK promoter ..............................................................................
Recommended publications
  • Retrocopy Contributions to the Evolution of the Human Genome Robert Baertsch*1, Mark Diekhans1, W James Kent1, David Haussler1 and Jürgen Brosius2

    Retrocopy Contributions to the Evolution of the Human Genome Robert Baertsch*1, Mark Diekhans1, W James Kent1, David Haussler1 and Jürgen Brosius2

    BMC Genomics BioMed Central Research article Open Access Retrocopy contributions to the evolution of the human genome Robert Baertsch*1, Mark Diekhans1, W James Kent1, David Haussler1 and Jürgen Brosius2 Address: 1Center for Biomolecular Science and Engineering, University of California Santa Cruz, Santa Cruz, California 95064, USA and 2Institute of Experimental Pathology, ZMBE, University of Münster, Von-Esmarch-Str. 56, D-48149, Münster, Germany Email: Robert Baertsch* - [email protected]; Mark Diekhans - [email protected]; W James Kent - [email protected]; David Haussler - [email protected]; Jürgen Brosius - [email protected] * Corresponding author Published: 8 October 2008 Received: 17 March 2008 Accepted: 8 October 2008 BMC Genomics 2008, 9:466 doi:10.1186/1471-2164-9-466 This article is available from: http://www.biomedcentral.com/1471-2164/9/466 © 2008 Baertsch et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Evolution via point mutations is a relatively slow process and is unlikely to completely explain the differences between primates and other mammals. By contrast, 45% of the human genome is composed of retroposed elements, many of which were inserted in the primate lineage. A subset of retroposed mRNAs (retrocopies) shows strong evidence of expression in primates, often yielding functional retrogenes. Results: To identify and analyze the relatively recently evolved retrogenes, we carried out BLASTZ alignments of all human mRNAs against the human genome and scored a set of features indicative of retroposition.
  • Roles of the CSE1L-Mediated Nuclear Import Pathway in Epigenetic

    Roles of the CSE1L-Mediated Nuclear Import Pathway in Epigenetic

    Roles of the CSE1L-mediated nuclear import pathway PNAS PLUS in epigenetic silencing Qiang Donga,b,c, Xiang Lia,b,c, Cheng-Zhi Wangb, Shaohua Xuc, Gang Yuanc, Wei Shaoc, Baodong Liud, Yong Zhengb, Hailin Wangd, Xiaoguang Leic,e,f, Zhuqiang Zhangb,1, and Bing Zhua,b,g,1 aGraduate Program, Peking Union Medical College and Chinese Academy of Medical Sciences, 100730 Beijing, China; bNational Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, 100101 Beijing, China; cNational Institute of Biological Sciences, 102206 Beijing, China; dThe State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, 100085 Beijing, China; eBeijing National Laboratory for Molecular Sciences, Department of Chemical Biology, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; fPeking-Tsinghua Center for Life Sciences, Peking University, 100871 Beijing, China; and gCollege of Life Sciences, University of Chinese Academy of Sciences, 100049 Beijing, China Edited by Arthur D. Riggs, Beckman Research Institute of City of Hope, Duarte, CA, and approved March 21, 2018 (received for review January 17, 2018) Epigenetic silencing can be mediated by various mechanisms, CSE1L, a key player in the nuclear import pathway, as an es- and many regulators remain to be identified. Here, we report a sential factor for maintaining the repression of many methyl- genome-wide siRNA screening to identify regulators essential for ated genes. Mechanistically, CSE1L functions by facilitating maintaining gene repression of a CMV promoter silenced by DNA the nuclear import of certain cargo proteins that are essential methylation.
  • Supporting Online Material

    Supporting Online Material

    1 2 3 4 5 6 7 Supplementary Information for 8 9 Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic 10 retinopathy 11 12 *Samuel A. Mills, *Andrew I. Jobling, *Michael A. Dixon, Bang V. Bui, Kirstan A. Vessey, Joanna A. Phipps, 13 Ursula Greferath, Gene Venables, Vickie H.Y. Wong, Connie H.Y. Wong, Zheng He, Flora Hui, James C. 14 Young, Josh Tonc, Elena Ivanova, Botir T. Sagdullaev, Erica L. Fletcher 15 * Joint first authors 16 17 Corresponding author: 18 Prof. Erica L. Fletcher. Department of Anatomy & Neuroscience. The University of Melbourne, Grattan St, 19 Parkville 3010, Victoria, Australia. 20 Email: [email protected] ; Tel: +61-3-8344-3218; Fax: +61-3-9347-5219 21 22 This PDF file includes: 23 24 Supplementary text 25 Figures S1 to S10 26 Tables S1 to S7 27 Legends for Movies S1 to S2 28 SI References 29 30 Other supplementary materials for this manuscript include the following: 31 32 Movies S1 to S2 33 34 35 36 1 1 Supplementary Information Text 2 Materials and Methods 3 Microglial process movement on retinal vessels 4 Dark agouti rats were anaesthetized, injected intraperitoneally with rhodamine B (Sigma-Aldrich) to label blood 5 vessels and retinal explants established as described in the main text. Retinal microglia were labelled with Iba-1 6 and imaging performed on an inverted confocal microscope (Leica SP5). Baseline images were taken for 10 7 minutes, followed by the addition of PBS (10 minutes) and then either fractalkine or fractalkine + candesartan 8 (10 minutes) using concentrations outlined in the main text.
  • List of Genes Associated with Sudden Cardiac Death (Scdgseta) Gene

    List of Genes Associated with Sudden Cardiac Death (Scdgseta) Gene

    List of genes associated with sudden cardiac death (SCDgseta) mRNA expression in normal human heart Entrez_I Gene symbol Gene name Uniprot ID Uniprot name fromb D GTEx BioGPS SAGE c d e ATP-binding cassette subfamily B ABCB1 P08183 MDR1_HUMAN 5243 √ √ member 1 ATP-binding cassette subfamily C ABCC9 O60706 ABCC9_HUMAN 10060 √ √ member 9 ACE Angiotensin I–converting enzyme P12821 ACE_HUMAN 1636 √ √ ACE2 Angiotensin I–converting enzyme 2 Q9BYF1 ACE2_HUMAN 59272 √ √ Acetylcholinesterase (Cartwright ACHE P22303 ACES_HUMAN 43 √ √ blood group) ACTC1 Actin, alpha, cardiac muscle 1 P68032 ACTC_HUMAN 70 √ √ ACTN2 Actinin alpha 2 P35609 ACTN2_HUMAN 88 √ √ √ ACTN4 Actinin alpha 4 O43707 ACTN4_HUMAN 81 √ √ √ ADRA2B Adrenoceptor alpha 2B P18089 ADA2B_HUMAN 151 √ √ AGT Angiotensinogen P01019 ANGT_HUMAN 183 √ √ √ AGTR1 Angiotensin II receptor type 1 P30556 AGTR1_HUMAN 185 √ √ AGTR2 Angiotensin II receptor type 2 P50052 AGTR2_HUMAN 186 √ √ AKAP9 A-kinase anchoring protein 9 Q99996 AKAP9_HUMAN 10142 √ √ √ ANK2/ANKB/ANKYRI Ankyrin 2 Q01484 ANK2_HUMAN 287 √ √ √ N B ANKRD1 Ankyrin repeat domain 1 Q15327 ANKR1_HUMAN 27063 √ √ √ ANKRD9 Ankyrin repeat domain 9 Q96BM1 ANKR9_HUMAN 122416 √ √ ARHGAP24 Rho GTPase–activating protein 24 Q8N264 RHG24_HUMAN 83478 √ √ ATPase Na+/K+–transporting ATP1B1 P05026 AT1B1_HUMAN 481 √ √ √ subunit beta 1 ATPase sarcoplasmic/endoplasmic ATP2A2 P16615 AT2A2_HUMAN 488 √ √ √ reticulum Ca2+ transporting 2 AZIN1 Antizyme inhibitor 1 O14977 AZIN1_HUMAN 51582 √ √ √ UDP-GlcNAc: betaGal B3GNT7 beta-1,3-N-acetylglucosaminyltransfe Q8NFL0
  • Supplementary Information

    Supplementary Information

    Supplementary Information This text file includes: Supplementary Methods Supplementary Figure 1-13, 15-30 Supplementary Table 1-8, 16, 20-21, 23, 25-37, 40-41 1 1. Samples, DNA extraction and genome sequencing 1.1 Ethical statements and sample storage The ethical statements of collecting and processing tissue samples for each species are listed as follows: Myotis myotis: All procedures were carried out in accordance with the ethical guidelines and permits (AREC-13-38-Teeling) delivered by the University College Dublin and the Préfet du Morbihan, awarded to Emma Teeling and Sébastien Puechmaille respectively. A single M. myotis individual was humanely sacrificed given that she had lethal injuries, and dissected. Rhinolophus ferrumequinum: All the procedures were conducted under the license (Natural England 2016-25216-SCI-SCI) issued to Gareth Jones. The individual bat died unexpectedly and suddenly during sampling and was dissected immediately. Pipistrellus kuhlii: The sampling procedure was carried out following all the applicable national guidelines for the care and use of animals. Sampling was done in accordance with all the relevant wildlife legislation and approved by the Ministry of Environment (Ministero della Tutela del Territorio e del Mare, Aut.Prot. N˚: 13040, 26/03/2014). Molossus molossus: All sampling methods were approved by the Ministerio de Ambiente de Panamá (SE/A-29-18) and by the Institutional Animal Care and Use Committee of the Smithsonian Tropical Research Institute (2017-0815-2020). Phyllostomus discolor: P. discolor bats originated from a breeding colony in the Department Biology II of the Ludwig-Maximilians-University in Munich. Approval to keep and breed the bats was issued by the Munich district veterinary office.
  • Supplemental Materials ZNF281 Enhances Cardiac Reprogramming

    Supplemental Materials ZNF281 Enhances Cardiac Reprogramming

    Supplemental Materials ZNF281 enhances cardiac reprogramming by modulating cardiac and inflammatory gene expression Huanyu Zhou, Maria Gabriela Morales, Hisayuki Hashimoto, Matthew E. Dickson, Kunhua Song, Wenduo Ye, Min S. Kim, Hanspeter Niederstrasser, Zhaoning Wang, Beibei Chen, Bruce A. Posner, Rhonda Bassel-Duby and Eric N. Olson Supplemental Table 1; related to Figure 1. Supplemental Table 2; related to Figure 1. Supplemental Table 3; related to the “quantitative mRNA measurement” in Materials and Methods section. Supplemental Table 4; related to the “ChIP-seq, gene ontology and pathway analysis” and “RNA-seq” and gene ontology analysis” in Materials and Methods section. Supplemental Figure S1; related to Figure 1. Supplemental Figure S2; related to Figure 2. Supplemental Figure S3; related to Figure 3. Supplemental Figure S4; related to Figure 4. Supplemental Figure S5; related to Figure 6. Supplemental Table S1. Genes included in human retroviral ORF cDNA library. Gene Gene Gene Gene Gene Gene Gene Gene Symbol Symbol Symbol Symbol Symbol Symbol Symbol Symbol AATF BMP8A CEBPE CTNNB1 ESR2 GDF3 HOXA5 IL17D ADIPOQ BRPF1 CEBPG CUX1 ESRRA GDF6 HOXA6 IL17F ADNP BRPF3 CERS1 CX3CL1 ETS1 GIN1 HOXA7 IL18 AEBP1 BUD31 CERS2 CXCL10 ETS2 GLIS3 HOXB1 IL19 AFF4 C17ORF77 CERS4 CXCL11 ETV3 GMEB1 HOXB13 IL1A AHR C1QTNF4 CFL2 CXCL12 ETV7 GPBP1 HOXB5 IL1B AIMP1 C21ORF66 CHIA CXCL13 FAM3B GPER HOXB6 IL1F3 ALS2CR8 CBFA2T2 CIR1 CXCL14 FAM3D GPI HOXB7 IL1F5 ALX1 CBFA2T3 CITED1 CXCL16 FASLG GREM1 HOXB9 IL1F6 ARGFX CBFB CITED2 CXCL3 FBLN1 GREM2 HOXC4 IL1F7
  • High-Grade Glioneuronal Tumor with an ARHGEF2–NTRK1 Fusion Gene

    High-Grade Glioneuronal Tumor with an ARHGEF2–NTRK1 Fusion Gene

    Brain Tumor Pathology (2019) 36:121–128 https://doi.org/10.1007/s10014-019-00345-y CASE REPORT High‑grade glioneuronal tumor with an ARHGEF2–NTRK1 fusion gene Kazuhiko Kurozumi1 · Yoshiko Nakano2 · Joji Ishida1 · Takehiro Tanaka3 · Masatomo Doi4 · Junko Hirato5 · Akihiko Yoshida6 · Kana Washio7 · Akira Shimada7 · Takashi Kohno8 · Koichi Ichimura2 · Hiroyuki Yanai9 · Isao Date1 Received: 1 March 2019 / Accepted: 20 March 2019 / Published online: 22 April 2019 © The Japan Society of Brain Tumor Pathology 2019 Abstract Here, we report a highly unusual case of high-grade glioneuronal tumor with a neurotrophic tropomyosin receptor kinase (NTRK) fusion gene. A 13-year-old girl presented with headache and vomiting and MRI detected two cystic lesions bilaterally in the frontal areas with surrounding edema. The left larger tumor was removed by left frontal craniotomy. The tumor was diagnosed as a high-grade glioneuronal tumor, unclassifed. Methylation profling classifed it as a difuse leptomeningeal glioneuronal tumor (DLGNT) with low confdence. This tumor showed genotypes frequently found in DLGNT such as 1p/19q codeletion without IDH mutation and, however, did not have the typical DLGNT clinical and histological features. RNA sequencing identifed an ARHGEF2 (encoding Rho/Rac guanine nucleotide exchange factor 2)–NTRK1 fusion gene. The presence of recurrent NTRK fusion in glioneuronal tumors has an important implication in the clinical decision making and opens up a possibility of novel targeted therapy. Keywords Pediatric brain tumor · 1p19qLOH · RNA sequencing · NTRK1 Introduction diagnosis of glioneuronal tumors has been sometimes chal- lenging. However, unique molecular signatures have recently Mixed glioneuronal tumors are rare group of brain tumors been identifed, enabling creation of classifcation schemes that consist of glial and neuronal components.
  • Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice

    Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice

    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition 12-19-2010 Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P. Stewart Marshall University Hyoung Y. Kim University of Tennessee - Knoxville, [email protected] Arnold M. Saxton University of Tennessee - Knoxville, [email protected] Jung H. Kim Marshall University Follow this and additional works at: https://trace.tennessee.edu/utk_nutrpubs Part of the Animal Sciences Commons, and the Nutrition Commons Recommended Citation BMC Genomics 2010, 11:713 doi:10.1186/1471-2164-11-713 This Article is brought to you for free and open access by the Nutrition at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Nutrition Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Stewart et al. BMC Genomics 2010, 11:713 http://www.biomedcentral.com/1471-2164/11/713 RESEARCH ARTICLE Open Access Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P Stewart1, Hyoung Yon Kim2, Arnold M Saxton3, Jung Han Kim1* Abstract Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/ JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia.
  • CD29 Identifies IFN-Γ–Producing Human CD8+ T Cells With

    CD29 Identifies IFN-Γ–Producing Human CD8+ T Cells With

    + CD29 identifies IFN-γ–producing human CD8 T cells with an increased cytotoxic potential Benoît P. Nicoleta,b, Aurélie Guislaina,b, Floris P. J. van Alphenc, Raquel Gomez-Eerlandd, Ton N. M. Schumacherd, Maartje van den Biggelaarc,e, and Monika C. Wolkersa,b,1 aDepartment of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; bLandsteiner Laboratory, Oncode Institute, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; cDepartment of Research Facilities, Sanquin Research, 1066 CX Amsterdam, The Netherlands; dDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; and eDepartment of Molecular and Cellular Haemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands Edited by Anjana Rao, La Jolla Institute for Allergy and Immunology, La Jolla, CA, and approved February 12, 2020 (received for review August 12, 2019) Cytotoxic CD8+ T cells can effectively kill target cells by producing therefore developed a protocol that allowed for efficient iso- cytokines, chemokines, and granzymes. Expression of these effector lation of RNA and protein from fluorescence-activated cell molecules is however highly divergent, and tools that identify and sorting (FACS)-sorted fixed T cells after intracellular cytokine + preselect CD8 T cells with a cytotoxic expression profile are lacking. staining. With this top-down approach, we performed an un- + Human CD8 T cells can be divided into IFN-γ– and IL-2–producing biased RNA-sequencing (RNA-seq) and mass spectrometry cells. Unbiased transcriptomics and proteomics analysis on cytokine- γ– – + + (MS) analyses on IFN- and IL-2 producing primary human producing fixed CD8 T cells revealed that IL-2 cells produce helper + + + CD8 Tcells.
  • S41467-020-18249-3.Pdf

    S41467-020-18249-3.Pdf

    ARTICLE https://doi.org/10.1038/s41467-020-18249-3 OPEN Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain Lei Zhao1,2,17, Zhongqi Li 1,2,17, Joaquim S. L. Vong2,3,17, Xinyi Chen1,2, Hei-Ming Lai1,2,4,5,6, Leo Y. C. Yan1,2, Junzhe Huang1,2, Samuel K. H. Sy1,2,7, Xiaoyu Tian 8, Yu Huang 8, Ho Yin Edwin Chan5,9, Hon-Cheong So6,8, ✉ ✉ Wai-Lung Ng 10, Yamei Tang11, Wei-Jye Lin12,13, Vincent C. T. Mok1,5,6,14,15 &HoKo 1,2,4,5,6,8,14,16 1234567890():,; The molecular signatures of cells in the brain have been revealed in unprecedented detail, yet the ageing-associated genome-wide expression changes that may contribute to neurovas- cular dysfunction in neurodegenerative diseases remain elusive. Here, we report zonation- dependent transcriptomic changes in aged mouse brain endothelial cells (ECs), which pro- minently implicate altered immune/cytokine signaling in ECs of all vascular segments, and functional changes impacting the blood–brain barrier (BBB) and glucose/energy metabolism especially in capillary ECs (capECs). An overrepresentation of Alzheimer disease (AD) GWAS genes is evident among the human orthologs of the differentially expressed genes of aged capECs, while comparative analysis revealed a subset of concordantly downregulated, functionally important genes in human AD brains. Treatment with exenatide, a glucagon-like peptide-1 receptor agonist, strongly reverses aged mouse brain EC transcriptomic changes and BBB leakage, with associated attenuation of microglial priming. We thus revealed tran- scriptomic alterations underlying brain EC ageing that are complex yet pharmacologically reversible.
  • AZIN1 Purified Maxpab Rabbit Polyclonal Antibody (D01P)

    AZIN1 Purified Maxpab Rabbit Polyclonal Antibody (D01P)

    AZIN1 purified MaxPab rabbit polyclonal antibody (D01P) Catalog # : H00051582-D01P 規格 : [ 100 ug ] List All Specification Application Image Product Rabbit polyclonal antibody raised against a full-length human AZIN1 Western Blot (Tissue lysate) Description: protein. Immunogen: AZIN1 (NP_056962.2, 1 a.a. ~ 448 a.a) full-length human protein. Sequence: MKGFIDDANYSVGLLDEGTNLGNVIDNYVYEHTLTGKNAFFVGDLGKIVK KHSQWQNVVAQIKPFYTVKCNSAPAVLEILAALGTGFACSSKNEMALVQE enlarge LGVPPENIIYISPCKQVSQIKYAAKVGVNILTCDNEIELKKIARNHPNAKVLLHI ATEDNIGGEEGNMKFGTTLKNCRHLLECAKELDVQIIGVKFHVSSACKES Western Blot (Transfected QVYVHALSDARCVFDMAGEIGFTMNMLDIGGGFTGTEFQLEEVNHVISP lysate) LLDIYFPEGSGVKIISEPGSYYVSSAFTLAVNIIAKKVVENDKFPSGVEKTG SDEPAFMYYMNDGVYGSFASKLSEDLNTIPEVHKKYKEDEPLFTSSLWG PSCDELDQIVESCLLPELNVGDWLIFDNMGADSFHEPSAFNDFQRPAIYY MMSFSDWYEMQDAGITSDSMMKNFFFVPSCIQLSQEDSFSAEA Host: Rabbit enlarge Reactivity: Human Quality Control Antibody reactive against mammalian transfected lysate. Testing: Storage Buffer: In 1x PBS, pH 7.4 Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. Instruction: MSDS: Download Datasheet: Download Applications Western Blot (Tissue lysate) AZIN1 MaxPab rabbit polyclonal antibody. Western Blot analysis of AZIN1 expression in human placenta. Protocol Download Western Blot (Transfected lysate) Page 1 of 2 2016/5/23 Western Blot analysis of AZIN1 expression in transfected 293T cell line (H00051582-T02) by AZIN1 MaxPab polyclonal antibody. Lane 1: AZIN1 transfected lysate(49.50 KDa). Lane 2: Non-transfected lysate. Protocol
  • Feeling the Force: Role of Amotl2 in Normal Development and Cancer

    Feeling the Force: Role of Amotl2 in Normal Development and Cancer

    Department of Oncology and Pathology Karolinska Institute, Stockholm, Sweden FEELING THE FORCE: ROLE OF AMOTL2 IN NORMAL DEVELOPMENT AND CANCER Aravindh Subramani Stockholm 2019 All previously published papers were reproduced with permission from the publisher. Front cover was modified from ©Renaud Chabrier and illustrated by Yu-Hsuan Hsu Published by Karolinska Institute. Printed by: US-AB Stockholm © Aravindh Subramani, 2019 ISBN 978-91-7831-426-3 Feeling the force: Role of AmotL2 in normal development and cancer. THESIS FOR DOCTORAL DEGREE (Ph.D.) J3:04, Torsten N Wiesel, U410033310, Bioclinicum, Karolinska University Hospital, Solna, Stockholm Friday, April 12th, 2019 at 13:00 By Aravindh Subramani Principal Supervisor: Opponent: Professor. Lars Holmgren Professor. Marius Sudol Karolinska Institute National University of Singapore Department of Oncology-Pathology Mechanobiology Institute (MBI) Co-supervisor(s): Examination Board: Docent. Jonas Fuxe Docent. Kaisa Lehti Karolinska Institute Karolinska institute Department of Microbiology, Tumor and Cell Department of Microbiology and Tumor Biology Biology (MTC) center (MTC) Associate Professor. Johan Hartman Docent. Ingvar Ferby Karolinska Institute Uppsala University Department of Oncology-Pathology Department of Medical Biochemistry and Microbiology Docent. Mimmi Shoshan Karolinska Institute Department of Oncology-Pathology To my mom and dad “Real knowledge is to know the extent of one's ignorance.” (Confucius) ABSTRACT Cells that fabricate the body, dwell in a very heterogeneous environment. Self-organization of individual cells into complex tissues and organs at the time of growth and revival is brought about by the combinatory action of biomechanical and biochemical signaling processes. Tissue generation and functional organogenesis, requires distinct cell types to unite together and associate with their corresponding microenvironment in a spatio-temporal manner.